Jiménez-Huerta J, Alarcón-Alcántara MD, Flores-Méndez VM, Gutiérrez-Ramírez A

Language: Spanish
References: 17
Page: 115-120
PDF size: 212.93 Kb.

ABSTRACT

Introduction. The World Health Organization (WHO) defines preterm birth as birth before 37 weeks of gestation prematurity being 69% of perinatal mortality and is considered the leading cause of infant death after the first month of life. Objective.To compare orciprenaline and atosiban in the treatment of preterm labor in Hospital Juárez de México. Material and methods. Prospective, comparative clinical, integrating 56 patients between 28 and 34 weeks of gestation, with cervical and uterine activity changes. Results. The utero-inhibition atosiban was found in 92.9 patients, only 2 patients finding fault. Otherwise, metaproterenol with a 66.7% success, with overall success difference between groups with p-value = 0.0325. The answer tocolytic atosiban is independent of demographic variables of the patients and a higher incidence of cardiovascular events in the metaproterenol group with p ≤ 0.0001. Conclusions. Patients managed with atosiban immediate response to the drug was well tolerated, with minimal adverse effects.

REFERENCES

1. Cabero Roura L. Parto prematuro. 1a. Ed. Buenos Aires: Editorial Médica Panamericana; 2004, p. 145-79.

2. Goldenberg RL, et al. Epidemiology and causes of preterm birth. Lancet 2008; 371: 75-84.

3. Husslein P, et al. Atosiban versus usual care for the management of preterm labor. J Perinatal Med 2007; 35: 305-13.

4. Nin: Consensus Development conference statement. Antenatal corticosteroids revisited: repeat courses. August 2000.

5. Ballard PL. Scientific basis and therapeutic regimens for use of antenatal glucocorticoids. Am J Obstet Gynecol 1995; 173: 254-64.

6. Torsten M, et al. Barusiban, A new high potent and long-acting oxitocin antagonist: pharmacokinetic and pharmacodynamic comparison with atosiban in a cynomolgus monkey model of preterm labor. J Clin Endocrinol Metab 2005; 90(4): 2275-91.

7. De la Fuente P, De la Fuente L. Encuestas SEGO. Tratamiento de la amenaza de parto pretérmino en los hospitales españoles. Prog Obstets Ginecol 2008; 51: 28-37.

8. Ortiz RME, et al. Uteroinhibidores actuales para el manejo de parto pretérmino. An Med (Mex) 2010; 55(2): 85-91.

9. Laterra, et al. Guía de Prácticas Clínicas. Amenaza de Parto Prematuro. Rev Hosp Mat Inf Ramón Sarda 2003; 22 (1).

10. Sanchez, et al. Efficacy of maintenance therapy after acute tocolysis. Am J Obstet Gynecol 1999; 181: 484-90.

11. Schmith T. Selective use of fibronectin detection after cervical lengf measurement to predict spontaneous preterm deliver in women with preterm mabor. Am J Obstet Ginecol 2006; 194: 138-43.

12. Paeceman AM. Fetal fibronectin as a predictor of preterm birth in patients with symptoms. Am J Obstet Gynecol 1997; 177: 13-8.

13. Masatoshi Sakai. The preterm labor index and fetal fibronectin for prediction of preterm delivery with intac membranes. The American College of Obstetricians and Gynecologists 2003; 101: 123-8.

14. Swart, et al. Visual Compatibility of atosiban acetate with four drugs. Am J Health-syst Phar 2005; 62: 2459-63.

15. Romero, Roberto, Sibai, et al. An oxytocin receptor antagonist atosiban in the treatment of preterm labor: a randomized double-blind, placebo-controlled trial with tocolytic rescue. Am J Obstet Gynecol 2000; 182(5): 1173-83.

16. Moutquin JM, et al. Double-blind randomized, controlled trial of atosiban and beta-adrenergic agonista in the tratment of preterm labor. Am J Obstet Gynecol 2002; 182: 1191-9.

17. Magdaleno F, Sancha M, López S, González A. Tratamiento tocolítico mas allá de las 48 horas en la amenaza de parto pretérmino. Folia Clin Obstet Ginecol 2011; 1: 3-24.